JP2013532971A5 - - Google Patents

Download PDF

Info

Publication number
JP2013532971A5
JP2013532971A5 JP2013515914A JP2013515914A JP2013532971A5 JP 2013532971 A5 JP2013532971 A5 JP 2013532971A5 JP 2013515914 A JP2013515914 A JP 2013515914A JP 2013515914 A JP2013515914 A JP 2013515914A JP 2013532971 A5 JP2013532971 A5 JP 2013532971A5
Authority
JP
Japan
Prior art keywords
antigen
homodimeric protein
protein according
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013515914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/060628 external-priority patent/WO2011161244A1/en
Publication of JP2013532971A publication Critical patent/JP2013532971A/ja
Publication of JP2013532971A5 publication Critical patent/JP2013532971A5/ja
Withdrawn legal-status Critical Current

Links

JP2013515914A 2010-06-25 2011-06-24 ホモ二量体タンパク質コンストラクト Withdrawn JP2013532971A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35851310P 2010-06-25 2010-06-25
EP10167291.3 2010-06-25
EP10167291 2010-06-25
US61/358,513 2010-06-25
PCT/EP2011/060628 WO2011161244A1 (en) 2010-06-25 2011-06-24 Homodimeric protein constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016154365A Division JP6538622B2 (ja) 2010-06-25 2016-08-05 ホモ二量体タンパク質コンストラクト

Publications (2)

Publication Number Publication Date
JP2013532971A JP2013532971A (ja) 2013-08-22
JP2013532971A5 true JP2013532971A5 (https=) 2014-08-14

Family

ID=42983487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013515914A Withdrawn JP2013532971A (ja) 2010-06-25 2011-06-24 ホモ二量体タンパク質コンストラクト
JP2016154365A Active JP6538622B2 (ja) 2010-06-25 2016-08-05 ホモ二量体タンパク質コンストラクト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016154365A Active JP6538622B2 (ja) 2010-06-25 2016-08-05 ホモ二量体タンパク質コンストラクト

Country Status (10)

Country Link
US (3) US10590195B2 (https=)
EP (2) EP3441085A1 (https=)
JP (2) JP2013532971A (https=)
KR (2) KR20130087517A (https=)
CN (1) CN102985109B (https=)
AU (1) AU2011268934B2 (https=)
CA (1) CA2803058C (https=)
DK (1) DK2585107T3 (https=)
RU (1) RU2624041C2 (https=)
WO (1) WO2011161244A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862878B1 (en) 2003-02-25 2022-11-02 Nykode Therapeutics ASA Modified antibody
CN102985109B (zh) 2010-06-25 2016-05-11 瓦西博迪公司 同型二聚体蛋白质构建体
BR112014015016B1 (pt) * 2011-12-21 2023-10-03 Nykode Therapeutics ASA Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
KR102682118B1 (ko) * 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
BR112019005895A2 (pt) 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
EP3678699A1 (en) * 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
AU2021253641A1 (en) * 2020-04-07 2022-10-27 Evaxion Biotech A/S Neoepitope immunotherapy with APC targeting unit
AU2021262521A1 (en) 2020-05-01 2022-12-08 Nykode Therapeutics ASA Betacoronavirus prophylaxis and therapy
US20230355733A1 (en) * 2020-07-14 2023-11-09 Evaxion Biotech A/S APC targeting units for immunotherapy
IL305777A (en) 2021-03-26 2023-11-01 Nykode Therapeutics ASA Medical combination for cancer treatment
WO2022233851A1 (en) 2021-05-03 2022-11-10 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
KR20240007235A (ko) 2021-05-10 2024-01-16 니코데 테라퓨틱스 에이에스에이 관용-유도 컨스트럭트 및 조성물 및 면역 장애의 치료를 위한 그들의 용도
EP4337247A1 (en) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2022238420A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunostimulatory compounds
IL308312A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Expression from a combination of inhibitory structures and compounds
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
JP2024540322A (ja) 2021-11-03 2024-10-31 ナイコード セラピューティクス アルメン アクスイェ セルスカプ SARS-CoV-2によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン
EP4608436A1 (en) 2022-10-25 2025-09-03 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5646016A (en) 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
AU5361794A (en) 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
DE69725857T2 (de) 1996-08-14 2004-07-29 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Vektor für polynukleotidimpfstoffe
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
ATE345780T1 (de) 2001-07-13 2006-12-15 Nanocarrier Co Ltd Lyophilisierende zusammensetzung von wirkstoff- verkapselnder polymer-mizelle und verfahren zu ihrer herstellung
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
CA2474002A1 (en) 2002-01-18 2003-07-24 Bjarne Bogen Bispecific antibody dna constructs for intramuscular administration
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
EP2862878B1 (en) * 2003-02-25 2022-11-02 Nykode Therapeutics ASA Modified antibody
DE602004027902D1 (de) * 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
CA2621371C (en) * 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US20090010948A1 (en) * 2006-12-15 2009-01-08 The University Of Hong Kong Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
BRPI0720647A2 (pt) * 2006-12-29 2014-01-14 Osprey Pharmaceuticals Usa Inc Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos
CA2739608A1 (en) 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
CN102985109B (zh) 2010-06-25 2016-05-11 瓦西博迪公司 同型二聚体蛋白质构建体
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules

Similar Documents

Publication Publication Date Title
JP2013532971A5 (https=)
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
RU2013103335A (ru) Конструкции гомодимерных белков
Raghuwanshi et al. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein
Zhang et al. Peptide-based nanovaccines in the treatment of cervical cancer: a review of recent advances
JP5984388B2 (ja) 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン
Fan et al. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes
JP2015529678A5 (https=)
JP2015508284A5 (https=)
JP2008541768A5 (https=)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
ES2775278T3 (es) Composición formada por un antígeno ligado a un ligando de la superfamilia TNF
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
JP2015509707A5 (https=)
JP2012509071A5 (https=)
JP2016516723A5 (https=)
Gupta et al. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases
KR20160105452A (ko) Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
CN104039833A (zh) 针对hpv的疫苗
US20250099575A1 (en) Mrna vaccine
CA2831294A1 (en) Compositions and methods to immunize against hepatitis c virus
CN105143251B (zh) 流感核蛋白疫苗
AU2021307553A1 (en) APC targeting units for immunotherapy
Kawai et al. Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses
JP2021515588A5 (https=)